INTERVENTION 1:	Intervention	0
Intent-To-Treat	Intervention	1
Participants received a single dose of 50 μg Lymphoseek radiolabeled with 0.5 or 2.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes.	Intervention	2
radiolabeled	BAO:0000036	56-68
dye	CHEBI:37958	105-108
lymph	UBERON:0002391	45-50
lymph	UBERON:0002391	113-118
lymph	UBERON:0002391	157-162
Inclusion Criteria:	Eligibility	0
The patient has provided written informed consent with HIPAA authorization.	Eligibility	1
patient	HADO:0000008,OAE:0001817	4-11
The patient is a candidate for surgical intervention, with lymph node mapping being a part of the surgical plan.	Eligibility	2
patient	HADO:0000008,OAE:0001817	4-11
lymph	UBERON:0002391	59-64
part of	BAO:0090002,BFO:0000050	86-93
The patient is at least 18 years of age at the time of consent.	Eligibility	3
patient	HADO:0000008,OAE:0001817	4-11
age	PATO:0000011	36-39
time	PATO:0000165	47-51
The patient has an ECOG performance status of Grade 0 - 2 (see Appendix A).	Eligibility	4
patient	HADO:0000008,OAE:0001817	4-11
The patient has a clinical negative node status at the time of study entry (i.e. T0-4, N0, M0, see Appendix D and E).	Eligibility	5
patient	HADO:0000008,OAE:0001817	4-11
time	PATO:0000165	55-59
If of childbearing potential, the patient has a negative pregnancy test within 72 hours prior to administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year.	Eligibility	6
patient	HADO:0000008,OAE:0001817	34-41
year	UO:0000036	201-205
Melanoma Patients	Eligibility	7
melanoma	HP:0002861,DOID:1909	0-8
The patient has a diagnosis of primary melanoma. Breast Cancer Patients	Eligibility	8
patient	HADO:0000008,OAE:0001817	4-11
patient	HADO:0000008,OAE:0001817	63-70
melanoma	HP:0002861,DOID:1909	39-47
breast cancer	DOID:1612	49-62
The patient has a diagnosis of primary breast cancer.	Eligibility	9
patient	HADO:0000008,OAE:0001817	4-11
breast cancer	DOID:1612	39-52
Patients with pure ductal carcinoma in situ (DCIS) or non-invasive carcinoma if lymph node biopsy is part of the surgical plan.	Eligibility	10
ductal carcinoma in situ	HP:0030075,DOID:0060074	19-43
carcinoma	HP:0030731,DOID:305	26-35
carcinoma	HP:0030731,DOID:305	67-76
lymph	UBERON:0002391	80-85
part of	BAO:0090002,BFO:0000050	101-108
Exclusion Criteria:	Eligibility	11
The patient is pregnant or lactating.	Eligibility	12
patient	HADO:0000008,OAE:0001817	4-11
The patient has clinical or radiological evidence of metastatic cancer including palpably abnormal or enlarged lymph nodes (i.e., all patients should be any T,N0,M0, see Appendix D and E).	Eligibility	13
patient	HADO:0000008,OAE:0001817	4-11
patient	HADO:0000008,OAE:0001817	134-141
cancer	DOID:162	64-70
lymph	UBERON:0002391	111-116
t	CHEBI:36371,BAO:0001260	0-1
t	CHEBI:36371,BAO:0001260	6-7
t	CHEBI:36371,BAO:0001260	10-11
t	CHEBI:36371,BAO:0001260	55-56
t	CHEBI:36371,BAO:0001260	58-59
t	CHEBI:36371,BAO:0001260	60-61
t	CHEBI:36371,BAO:0001260	136-137
t	CHEBI:36371,BAO:0001260	140-141
t	CHEBI:36371,BAO:0001260	157-158
The patient has a known hypersensitivity to Lymphazurin.	Eligibility	14
patient	HADO:0000008,OAE:0001817	4-11
hypersensitivity	GO:0002524,DOID:1205	24-40
The patient has participated in another investigational drug study within 30 days of scheduled surgery.	Eligibility	15
patient	HADO:0000008,OAE:0001817	4-11
drug	CHEBI:23888	56-60
surgery	OAE:0000067	95-102
Melanoma Patients	Eligibility	16
melanoma	HP:0002861,DOID:1909	0-8
The patient has a tumor with a Breslow depth less than 0.75mm.	Eligibility	17
patient	HADO:0000008,OAE:0001817	4-11
Patient has had preoperative chemotherapy, immunotherapy, or radiation therapy.	Eligibility	18
patient	HADO:0000008,OAE:0001817	0-7
Patient has been diagnosed with a prior invasive melanoma that would occur on the same body region or potentially draining to the same nodal basin or patients with truncal or extremity primary melanoma who has had a prior breast cancer potentially draining to the same axillary nodal basin.	Eligibility	19
patient	HADO:0000008,OAE:0001817	0-7
patient	HADO:0000008,OAE:0001817	150-157
melanoma	HP:0002861,DOID:1909	49-57
melanoma	HP:0002861,DOID:1909	193-201
breast cancer	DOID:1612	222-235
Patient has undergone node basin surgery of any type or radiation to the nodal basin(s) potentially draining the primary melanoma.	Eligibility	20
patient	HADO:0000008,OAE:0001817	0-7
surgery	OAE:0000067	33-40
melanoma	HP:0002861,DOID:1909	121-129
Patient has undergone a wide excision for their primary melanoma (>1 cm in dimension) or complex reconstruction (rotation, free flap, or skin graft of any type).	Eligibility	21
patient	HADO:0000008,OAE:0001817	0-7
melanoma	HP:0002861,DOID:1909	56-64
Breast Cancer Patients	Eligibility	22
breast cancer	DOID:1612	0-13
The patient has bilateral primary breast cancers or multiple tumors within their breast.	Eligibility	23
patient	HADO:0000008,OAE:0001817	4-11
bilateral	HP:0012832	16-25
breast	UBERON:0000310	34-40
breast	UBERON:0000310	81-87
Patient has had prior surgical procedures such as breast implants, reduction mammoplasty, or axillary surgery.	Eligibility	24
patient	HADO:0000008,OAE:0001817	0-7
breast	UBERON:0000310	50-56
mammoplasty	OAE:0001160	77-88
surgery	OAE:0000067	102-109
Patient is scheduled for bilateral mastectomy unless for cosmetic reasons and the contraindicated breast will not undergo lymph node mapping.	Eligibility	25
patient	HADO:0000008,OAE:0001817	0-7
bilateral	HP:0012832	25-34
cosmetic	CHEBI:64857	57-65
breast	UBERON:0000310	98-104
lymph	UBERON:0002391	122-127
Patient has had preoperative radiation therapy to the affected breast or axilla.	Eligibility	26
patient	HADO:0000008,OAE:0001817	0-7
affected	HP:0032320	54-62
breast	UBERON:0000310	63-69
Outcome Measurement:	Results	0
Concordance of Blue Dye and Lymphoseek	Results	1
dye	CHEBI:37958	20-23
The proportion of lymph nodes detected intraoperatively by blue dye that were also detected by Lymphoseek.	Results	2
lymph	UBERON:0002391	18-23
lymph	UBERON:0002391	95-100
dye	CHEBI:37958	64-67
Time frame: Surgery after injections of Lymphoseek and blue dye	Results	3
time	PATO:0000165	0-4
surgery	OAE:0000067	12-19
dye	CHEBI:37958	60-63
Results 1:	Results	4
Arm/Group Title: Intent-To-Treat	Results	5
Arm/Group Description: Participants received a single dose of 50 μg Lymphoseek radiolabeled with 0.5 or 2.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes.	Results	6
radiolabeled	BAO:0000036	79-91
dye	CHEBI:37958	128-131
lymph	UBERON:0002391	68-73
lymph	UBERON:0002391	136-141
lymph	UBERON:0002391	180-185
Overall Number of Participants Analyzed: 133	Results	7
Overall Number of Units Analyzed	Results	8
Type of Units Analyzed: Lymph Nodes  Measure Type: NumberNumber (95% Confidence Interval)Unit of Measure: Proportion of Lymph Nodes: 1.0000        (0.9840 to 1.0000)	Results	9
lymph	UBERON:0002391	24-29
lymph	UBERON:0002391	120-125
Adverse Events 1:	Adverse Events	0
Total: 8/153 (5.23%)	Adverse Events	1
Bradycardia  [1]1/153 (0.65%)	Adverse Events	2
bradycardia	HP:0001662	0-11
Tachycardia  [1]1/153 (0.65%)	Adverse Events	3
tachycardia	HP:0001649	0-11
Cellulitis  [1]2/153 (1.31%)	Adverse Events	4
cellulitis	HP:0100658,DOID:3488	0-10
Herpes Zoster Ophthalmic  [1]1/153 (0.65%)	Adverse Events	5
herpes zoster	DOID:8536	0-13
Seroma  [1]1/153 (0.65%)	Adverse Events	6
Syncope  [1]1/153 (0.65%)	Adverse Events	7
syncope	HP:0001279	0-7
Asthma  [1]1/153 (0.65%)	Adverse Events	8
asthma	HP:0002099,DOID:2841	0-6
